beeldscherm schreef op 29 november 2017 09:14:
Plasma Protease C1-Inhibitor Treatment Market Will Rise at a Robust 20.0% CAGR for the Forecast Period of 2017 to 2025
...
One of the key drivers of the plasma protease C1-inhibitor treatment market is the increasing usage of plasma protease C1-inhibitor treatment drugs due to the increasing incidence of acute cases of hereditary angioedema (HAE) and prophylaxis. The emergence of C1-inhibitor is considered to be a major breakthrough among several drugs introduced in the plasma protease C1-inhibitor treatment market.
Increasing practice of administering prophylactic treatment process for HAE patient, demand for a new route of administration of C1-inhibitor drugs, rising demand for administering drugs subcutaneously among HAE patients are some other growth drivers of the plasma protease C1-inhibitor treatment market.
Apart from this, commercialization of drugs such as Ruconest in emerging markets of Asia Pacific is likely to boost the C1-inhibitor segment in the upcoming years.
ik zie de bloedplasma tekorten alweer oplopen....
www.digitaljournal.com/pr/3577762